Posted in | News | Medical Robotics

Department of Veterans Affairs’ Multi-Center Study Uses ReWalk Exoskeleton Systems

ReWalk Robotics Ltd. (“ReWalk” or “Company”), the leading global exoskeleton developer and manufacturer, announced that the Department of Veterans Affairs (“VA”) has publicly listed details of a national, multi-center study utilizing the Company’s Personal 6.0 Exoskeleton Systems.

The VA released full details of the study titled, “Exoskeleton Assisted-Walking in Persons With SCI: Impact on Quality of Life” on the clinical trials section of the National Institutes of Health (NIH) website. (www.clinicaltrials.gov Identifier: NCT02658656).

Several key components of the study outlined by the VA, include:

  • Enrollment of 160 participants nationwide
  • Eligibility criteria for study participants
  • Study start date: October 2016
  • Locations of six participating VA Medical Centers with Spinal Cord Injury Services in California, Florida, Massachusetts, Texas and Virginia

It was announced in January that the VA awarded a delivery order to Veterans Healthcare Supply Solutions (VHSS), the Service Disabled Veteran Owned Small Business (SDVOSB) authorized distributor of ReWalk Robotics, for six ReWalk exoskeleton systems to support this first-of-its-kind national study. ReWalk is the only FDA cleared exoskeleton technology for individuals with spinal cord injury. The Company has already shipped the order of six systems for the multi-center trial to the VA, and continues to work in coordination with the department as the study leads prepare for its launch this year.

“This VA clinical trial is groundbreaking in both its purpose and scope, and will undoubtedly provide a wealth of quality research data to the department’s already impressive research,” said ReWalk CEO Larry Jasinski. “ReWalk is glad to provide our technology to enable this critical national study.”

The Department of Veterans Affairs is the largest single healthcare provider to persons with Spinal Cord Injury (SCI) in the United States. This is the first study in the United States to examine the impact of exoskeleton use in a home or daily life setting. ReWalk has Class II FDA clearances for exoskeleton use in the rehabilitation and personal setting, with the latter intended for home and community use.

About ReWalk Personal 6.0

ReWalk Personal 6.0 is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury to stand upright and walk. The system provides user-initiated mobility through the integration of a wearable brace support, a computer-based control system and motion sensors. The system allows independent, controlled walking while mimicking the natural gait patterns of the legs. The ReWalk device is the most studied exoskeleton in the industry. Studies have identified a number of health benefits including: improved bladder and bowel function, improved mental health, improved sleep, reduced fatigue, decreased body fat, decreased pain and improved posture and balance.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.